Spinal Cord Injury Blunted Effects of Endothelin-1 on Ca²⁺ Transients and Calcium Current in Isolated Rat Cardiomyocytes

Y.-F. GUO[1*], A.-J. REN[2*], D.-Y. CHEN[1], W. YUAN[1], Y. CHEN[1], S.-H. GOU[1], L.-S. JIA[1], W.-J. YUAN[2,3], Y. LIU[1]

*These authors contributed equally to this work.

[1]Department of Orthopedics, Changzheng Hospital, Second Military Medical University, Shanghai, China, [2]Department of Physiology, Second Military Medical University, Shanghai, China, [3]Department of Neurobiology, Ningxia Medical University, Yinchuan, China

Summary

Plasma endothelin-1 (ET-1) levels are elevated in spinal cord injury (SCI), and ET-1 may be involved in the pathophysiology of this condition. However, its effects on contractile function of the heart of SCI rats are still unknown. To define more clearly the possiblel role of ET-1 following SCI, we investigated the effect of ET-1 on the contraction, calcium transients and L-type calcium current ($I_{Ca,L}$) in the cardiomyocytes of control and SCI rats. Sixteen Sprague-Dawley male rats aged 80-100 days and weighing 250-350 g were randomized into control and SCI groups. Fourteen days following compression injury to the spinal cord, effects of ET-1 on the contraction, calcium transients and $I_{Ca,L}$ were studied in the cardiomyocytes of control and SCI rats by the technique of simultaneous measurement of intracellular Ca²⁺ and contraction and by whole-cell configuration of the patch-clamp technique. In myocytes from control rats, ET-1 significantly increased contraction, the magnitude of Ca²⁺ transients and the peak amplitude of $I_{Ca,L}$. However, ET-1 had little effect on the amplitude of contraction, calcium transients and $I_{Ca,L}$ in myocytes from SCI rats. These results suggest that the positive inotropic effects of ET-1 on control myocardial contraction may be altered in pathological states such as SCI.

Corresponding author

Y. Liu, Department of Orthopaedics, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China. E-mail: liuyan318@yahoo.cn

Introduction

Endothelin-1 (ET-1) is a 21-amino acid peptide originally isolated from porcine aortic endothelial cells as a vasoconstricting agent (Yanagisawa *et al.* 1988). In addition to its potential vasoconstrictor effects, ET-1 produces a positive inotropic effect on the intact left ventricle (LV) and isolated myocytes from normal animals (Mebazaa *et al.* 1993, Chu *et al.* 2005, Cingolani *et al.* 2006, De Giusti *et al.* 2008). Recent studies suggest that the effects of ET-1 on normal myocardial contraction may be altered in pathological states (Cheng *et al.* 1996, Ito *et al.* 1997, Spinale *et al.* 1997, Brás-Silva *et al.* 2008). For example, Sakai *et al.* (1996) reported that following coronary artery occlusion in rats, the elevated plasma levels of ET-1 and myocardial accumulation of ET-1 were associated with a decline in LV pressure development. Treatment with ET-1 receptor blocker has been shown to improve cardiac function in congestive heart failure (CHF) and myocardial ischemia (Kiowski *et al.* 1995, Cheng *et al.* 1996, Spinale *et al.* 1997). In CHF, ET-1 produces a direct depression of cardiomyocyte contractile performance that is associated with a significant decrease in the peak Ca²⁺ transient (Suzuki *et al.* 1998).

Cardiovascular abnormalities after spinal cord injury (SCI) have been well documented in clinical studies (Teasell *et al.* 2000, Collins *et al.* 2006, Myers *et al.* 2007). The initial period after SCI is characterized by low arterial blood pressure and persistent bradycardia

(Collins *et al*. 2006, Furlan *et al*. 2008). With time, blood pressure control becomes volatile and can be characterized by episodes of extreme hypertension accompanied by pounding headache, slow heart rate, and upper body flushing. Individuals with spinal cord injury are reported to be at increased risk of mortality compared to healthy persons, and death among individuals with SCI is primarily due to cardiovascular abnormalities (Devivo *et al*. 1992). However, the reasons for this are uncertain. One possibility is that SCI increases the risk of unstable blood pressure and cardiac arrhythmias or other electrocardiographic abnormalities that may predispose patients to adverse cardiac events (Leaf *et al*. 1993, Prakash *et al*. 2002).

Spinal cord injury has been shown to induce an immediate increase in plasma ET-1 levels and a sustained increase in tissue ET-1 levels (Salzman *et al*. 1996, Uesugi *et al*. 1996, Peters *et al*. 2003). Recent experimental and clinical studies indicated a role for ET-1 in the pathophysiology of SCI (Salzman *et al*. 1996, Uesugi *et al*. 1998, Ogawa *et al*. 2008). To define more clearly the possible role of ET-1 following SCI, we investigated the effect of ET-1 on contraction, Ca^{2+} transient, and L-type calcium current ($I_{Ca,L}$) in rat ventricular myocytes.

Materials and Methods

This study was performed according to the guidelines for the care and use of laboratory animals published by U.S. National Academy Press in 1996 and the Guidelines for Animal Experiments of the Second Military Medical University of CPLA.

SCI model in rats

Sixteen Sprague-Dawley (SD) male rats aged 80-100 days and weighing 250-350 g were randomized into two groups. Group 1: Sham group (n=8). Group 2: Spinal cord injury (SCI) group (n=8). The SCI model in rats has been described in details previously (Xu *et al*. 1991, Liu *et al*. 1997). Briefly, male rats were subjected to chloral hydrate anesthesia (400 mg/kg, i.p.). After a T5–T6 laminectomy, SCI was induced using a New York University Impactor by dropping a 10 g weight. Animals subjected to identical surgical procedures, without impaction, served as sham-operated controls.

Cell isolation

Fourteen days after surgical procedures, single ventricular myocytes from the control and SCI group rats were isolated using an enzymatic dissociation procedure as described previously (Liu *et al*. 1995). Briefly, the animals were heparinized (500 IU/kg, i.p.) and were subjected to chloral hydrate anesthesia (400 mg/kg, i.p.). Hearts were removed quickly, and the aorta was cannulated and perfused by a Langendorff perfusion apparatus with normal Tyrode's solution. The heart was then perfused with nominally Ca^{2+}-free Tyrode's solution for 5 min at a rate of 10 ml/min followed by perfusion with the same solution containing collagenase I (0.6 mg/ml; Sigma) at 37 °C. Eight to ten minutes later, the ventricle was dissected, and cells were mechanically dispersed and stored in KB solution. This procedure consistently yielded an acceptable number of quiescent, relaxed ventricular cells. According to our procedure, we normally gained 10^6 cells/heart and three cells from each heart were analyzed.

Simultaneous measurement of intracellular Ca^{2+} and contraction

Myocytes were loaded with the fluorescent Ca^{2+}-sensitive indicator Fura-2 by incubation with the membrane-permeable acetoxymethyl ester (AM) form of Fura-2 (5 μM, Molecular Probes) for 30 min at room temperature. Myocytes were allowed to settle onto the coverslip that formed the base of the experimental chamber and were then superfused with Tyrode solution (see below for composition). The chamber was mounted on the stage of an inverted microscope (Nikon Diaphot) and Fura-2 fluorescence was elicited by alternate illumination with 340 and 380 nm light obtained with a rotating filter wheel (Cairn Research Ltd.) mounted in front of a Xenon lamp. The fluorescence emitted at 510 nm was monitored using a photomultiplier tube. The ratio of the fluorescence emitted at 510 nm during excitation at 340 nm to that emitted during excitation at 380 nm was used as a measurement of $[Ca^{2+}]_i$. The amplitude of the Ca^{2+} transient was measured as the difference between end diastolic $[Ca^{2+}]_i$ and the $[Ca^{2+}]_i$ at the peak of the rapidly rising phase of the Ca^{2+} transient (Isenberg *et al*. 1994).

Contraction (cell shortening) was measured optically with a video edge detector system (Rotatech, Norwalk, CA, USA) (Steadman *et al*. 1988). The image of a contracting myocyte was detected by a CCD TV camera (TM 524, PULNiX, Hants, UK) on the side port of the microscope and the camera signal was then fed into the edge detector circuitry. The system functioned at the frame rate of the camera (50 Hz), and the accuracy with

which the measurement cursors followed both ends of the myocyte were verified continuously on a TV monitor.

Electrophysiological measurements

Isolated rat ventricular myocytes were placed in a perfusion chamber and superfused with external solution at a flow rate of 1.5 ml/min. Patch electrodes were fabricated from borosilicate glass with a Micropipette Puller Model 97 (Sutter Instrument Company, California, USA). Its resistance was 2-4 MΩ when the electrode was filled with the internal solution. The potential of the electrode was adjusted to zero current between the internal solution and the external solution immediately before seal formation. After obtaining a gigaseal, a suction pulse was applied to establish the whole-cell mode. Series resistance was electronically compensated by 70-90 %.

$I_{Ca,L}$ was elicited by depolarization to +10 mV for 400 ms, following a 300-ms prepulse to –40 mV from the holding potential of –80 mV at 15 s intervals. Any preparations showing insufficient voltage control were excluded from the study. With K$^+$ currents blocked using the cesium electrode solution, and Na$^+$ currents inactivated at –40 mV, transient inward currents invoked by step depolarization from –40 to 10 mV were considered to be $I_{Ca,L}$ (Dukes *et al*. 1991). This protocol elicited a time- and voltage-dependent current which had all the characteristics of $I_{Ca,L}$. These currents were completely blocked by verapamil. Membrane capacitance was measured using the calibrated capacity compensation circuit of the voltage clamp amplifier using a 5 mV hyperpolarizing pulse. We expressed all the current data as current density (pA/pF) by normalizing the peak $I_{Ca,L}$ for each cell to cell capacitance. The current-voltage (I-V) relationship of $I_{Ca,L}$ was obtained by plotting the peak current amplitude in response to 400 ms voltage pulses from –50 to +60 mV with 10 mV increments every 15 s. In the present study, we studied the effects of 1 nM, 5 nM and 10 nM ET-1 on Ca^{2+} currents and found that ET-1 dose-dependently increased Ca^{2+} currents in myocytes of control rats. We therefore used the dose of 5 nM for all further experiments.

All experiments were performed at room temperature (20-23 °C). Command pulses were delivered and data were acquired with a patch-clamp amplifier (EPC-10, HEKA Elektronik Dr. Schulze GmbH, Pfalz, Germany) controlled by the PULSE software connected to a computer.

Experimental solutions

The Tyrode's solution (as mmol/l): NaCl 135, KCl 5.4, CaCl$_2$ 1.2, MgCl$_2$ 1, NaH$_2$PO$_4$ 0.33, HEPES 5, and glucose 11 (pH adjusted to 7.4 with NaOH). Nominally Ca^{2+}-free Tyrode's solution was prepared by omitting CaCl$_2$. The KB solution (as mmol/l): KCl 30, L-glutamic acid 50, KOH 80, KH$_2$PO$_4$ 30, taurine 20, HEPES 10, EGTA 0.5, MgSO$_4$ 3 and glucose 10 (pH adjusted to 7.4 with KOH). The external solution (as mmol/l): NaCl 133.5, CsCl 4.0, CaCl$_2$ 1.8, MgCl$_2$ 1.2, glucose 11.1, HEPES 10 (pH adjusted to 7.4 with NaOH). The internal solution (as mmol/l): CsCl 120, EGTA 10, Na$_2$ATP 5, HEPES 10 (pH adjusted to 7.2 with CsOH).

Statistical analysis

Data were presented as means ± S.D. and were analyzed using analysis of variance followed by Student-Newman-Keuls *post-hoc* test to assess the significance level. Differences between two groups were considered significant when P<0.05.

Results

Effects of ET-1 on Ca^{2+} transients and contraction in myocytes from control and SCI rats

We first examined the characteristics of the effects of endothelin-1 at 5 nmol/l on the Ca^{2+} transients and cell shortening in myocytes isolated from control rats. Figure 1 shows representative records of contraction and the associated Ca^{2+} transients prior to and during application of ET-1 for 10 min in control ventricular myocytes loaded with Fura-2. ET-1 at 5 nmol/l induced a significant increase in Fura-2 ratio at 5 nmol/l concentration (0.115±0.012 *vs.* 0.089±0.011, n=12, P<0.01), which was associated with an increase in cell shortening (7.13±0.78 μm *vs.* 4.89±0.70 μm, n=12, P<0.01) (Fig. 2). However, ET-1 at 5 nmol/l had little effect on the amplitude of contraction and calcium transients in myocytes from SCI rats (Figs 2 and 3).

Effect of ET-1 on $I_{Ca,L}$ in myocytes from control and SCI rats

Figure 4a shows a time course of the effect of 5 nmol/l ET-1 on peak $I_{Ca,L}$ density evoked by a step to +10 mV in a single myocyte of control or SCI rat. In control rat myocytes, application of 5 nmol/l ET-1 to the bath induced an increase in $I_{Ca,L}$ that started at 3 min, reached a maximum value after 6-8 min, and reversed by washout. However, 5 nmol/l ET-1 did not increase $I_{Ca,L}$

Fig. 1. Representative records of contractions (**a** and **b**) and the associated Ca^{2+} transients (**c** and **d**) of control rat myocytes prior to (**a** and **c**) and after (**b** and **d**) application of ET-1 at 5 nmol/l for 10 min.

Fig. 2. Representative records of contractions (**a** and **b**) and the associated Ca^{2+} transients (**c** and **d**) of SCI rat myocytes prior to (**a** and **c**) and after (**b** and **d**) application of ET-1 at 5 nmol/l for 10 min.

significantly in SCI group myocytes.

Figures 4b and 4c show the average current density-voltage before and after administration of 5 nmol/l ET-1 in control and SCI rat myocytes, respectively. A significant increase in current density was observed in the voltage range between –10 and +30 mV after application of ET-1 to the bath solution of control rat myocytes. I$_{Ca,L}$ significantly increased at test potentials positive from –10 to +30 mV. However, in SCI


Fig. 3. (**a**) Contraction amplitude in control and SCI group cells before and after application of ET-1 at 5 nmol/l. (**b**) Ca^{2+} transient amplitude for control and SCI group cells before and after application of ET-1 at 5 nmol/l. Contraction amplitude and Ca^{2+} transient amplitude were significantly increased after application of 5 nmol/l ET-1 (n=12, ** P<0.01) in control group cells, but not changed significantly in SCI group cells (n=12, P>0.05). Data are means ± S.D.

rat myocytes, ET-1 had little effect on I$_{Ca,L}$ (Fig. 4c), which is consistent with the lack effect of ET-1 on contraction and calcium transients.

Discussion

The present study investigated the effects of ET-1 on the contraction, calcium transients and L-type calcium current in the control and SCI rat cardiomyocytes. We performed contractile force measurements and voltage-clamp analysis of membrane currents and our results shows that ET-1 significantly increased contractile force by enhancement of Ca^{2+} influx through the L-type calcium channels in control rat myocytes. However, ET-1 had little effect on the amplitude of contraction, calcium transients and I$_{Ca,L}$ in myocytes of SCI rats.

It is generally accepted that calcium influx is the main factor eliciting cardiac contractions (Vites *et al.* 1996). Thus, increased I$_{Ca,L}$ might play the most important role in increasing cardiac contractility. The increase in I$_{Ca,L}$ induced by ET-1 may contribute to the

Fig. 4. (**a**) A time course of the effect of 5 nmol/l ET-1 on peak $I_{Ca,L}$ density evoked by a step to +10 mV in a single myocyte of control rat (o) or SCI rat (□). Representative traces of $I_{Ca,L}$ of control myocyte corresponding to the points indicated at top are shown at bottom. (**b,c**) Effect of 5 nmol/l ET-1 on current-voltage(I-V) relationship curves of myocytes (n=20) of control rat (**b**) or SCI rat (**c**). I-V curves were obtained by plotting peak $I_{Ca,L}$ *vs.* test potential. Exposure to 5 nmol/l ET-1 resulted in a significant increase in peak $I_{Ca,L}$ of control rat myocytes but lack effect in peak $I_{Ca,L}$ of SCI rat myocytes. * $p<0.05$ *vs.* control, ** $p<0.01$ *vs.* control.

increase in Ca²⁺ transients probably by activation of Ca²⁺-induced Ca²⁺ release and trigger positive inotropic action induced by ET-1. The positive inotropic effects of ET-1

on control myocytes are supposed to be induced by G_q protein-mediated activation of protein kinase C and a consequent variable combination of elevation of cytosolic calcium levels and myofilament sensitization to calcium (Sugden 2003, Sugden and Clerk 2005).

Based on our present experimental findings, it is rather difficult to identify the mechanisms underlying the absence of the inotropic effect of ET-1 in SCI rat myocytes. It could be due to the downregulation of ET-1 receptors. It has been reported that 14 days following compression injury of the spinal cord, there was a significant upregulation in both the immunoexpression and number of astrocytes expressing the ET_B receptor in both gray and white matter. Furthermore, ET_B receptor immunoreactivity in ependymal cells and ET_A receptor immunoreactivity in primary afferent fibers almost disappeared (Peters *et al.* 2003). These results showed that there might be upregulation or downregulation of ET-1 receptors after SCI. However, alterations in ET-1 receptor density or affinity have not been reported in SCI rat hearts. The absent inotropic effect of ET-1 in SCI rat myocytes could also be due to desensitization of ET-1 receptors, which might result in the lack effect of ET-1 on $I_{Ca,L}$ current and the consequent lack effect ET-1 on contraction.

ET-1 receptors are coupled to G_q proteins and protein kinase C, thereby potentially exerting positive inotropic effects (Sugden 2003, Sugden and Clerk 2005). ET-1 receptors can also couple to G_i proteins and inhibit adenylyl cyclase, thereby potentially exerting negative inotropic effects (Hilal-Dandan *et al.* 1994). Thus the functional activity of G_i proteins may be increased in SCI and antagonize the positive inotropic effects induced by G_q activation. An alternative possibility is that protein kinase C in SCI rat myocytes cannot be activated by ET-1. All the above possibilities need further study.

Studies on the effect of ET-1 on the voltage-dependent calcium current in cardiac myocytes under conventional whole cell configuration have yielded conflicting results – increase (Bkaily *et al.* 1995), decrease (Bányász *et al.* 2001) or no effect (Habuchi *et al.* 1992). These contradictory data may be caused by the wide differences in experimental conditions, including different species, tissues, preparations and temperatures. In this study, we observed that exogenous ET-1 increased $I_{Ca,L}$ and had a positive inotropic effect in the control rat myocytes. However, ET-1 has no inotropic effects in SCI rat myocytes. Further studies are needed to investigate mechanisms underlying the absence of inotropic effect of ET-1 in SCI rat myocytes.

References

BÁNYÁSZ T, MAGYAR J, KÖRTVÉLY A, SZIGETI G, SZIGLIGETI P, PAPP Z, MOHÁCSI A, KOVÁCS L, NÁNÁSI PP: Different effects of endothelin-1 on calcium and potassium currents in canine ventricular cells. *Naunyn Schmiedebergs Arch Pharmacol* **363**: 383-390, 2001.

BKAILY G, WANG S, BUI M, MÉNARD D: ET-1 stimulates Ca^{2+} currents in cardiac cells. *J Cardiovasc Pharmacol* **26** (Suppl 3): S293-S296, 1995.

BRÁS-SILVA C, LEITE-MOREIRA AF: Myocardial effects of endothelin-1. *Rev Port Cardiol* **27**: 925-951, 2008.

FRANCIS B, WINAVER J, KARRAM T, HOFFMAN A, ABASSI Z: Renal and systemic effects of chronic blockade of ET_A or ET_B receptors in normal rats and animals with experimental heart failure. *J Cardiovasc Pharmacol* **44** (Suppl 1): S54-S58, 2004.

CINGOLANI HE, VILLA-ABRILLE MC, CORNELLI M, NOLLY A, ENNIS IL, GARCIARENA C, SUBURO AM, TORBIDONI V, CORREA MV, CAMILIÓNDE HURTADO MC, AIELLO EA: The positive inotropic effect of angiotensin II: role of endothelin-1 and reactive oxygen species. *Hypertension* **47**: 727-734, 2006.

CHU L, ZHANG JX, NOROTA I, ENDOH M: Differential action of a protein tyrosine kinase inhibitor, genistein, on the positive inotropic effect of endothelin-1 and norepinephrine in canine ventricular myocardium. *Br J Pharmacol* **144**: 430-442, 2005.

COLLINS HL, RODENBAUGH DW, DiCARLO SE: Spinal cord injury alters cardiac electrophysiology and increases the susceptibility to ventricular arrhythmias. *Prog Brain Res* **152**: 275-288, 2006.

DE GIUSTI VC, CORREA MV, VILLA-ABRILLE MC, BELTRANO C, YEVES AM, DE CINGOLANI GE, CINGOLANI HE, AIELLO EA: The positive inotropic effect of endothelin-1 is mediated by mitochondrial reactive oxygen species. *Life Sci* **83**: 264-271, 2008.

DEVIVO MJ, STOVER SL, BLACK KL: Prognostic factors for 12-year survival after spinal cord injury. *Arch Phys Med Rehabil* **73**: 156-162, 1992.

DUKES ID, MORAD M: The transient K^+ current in rat ventricular myocytes: evaluation of its Ca^{2+} and Na^+ dependence. *J Physiol Lond* **435**: 395-420, 1991.

FURLAN JC, FEHLINGS MG: Cardiovascular complications after acute spinal cord injury: pathophysiology, diagnosis, and management. *Neurosurg Focus* **25**: E13, 2008.

HABUCHI Y, TANAKA H, FURUKAWA T, TSUJIMURA Y, TAKAHASHI H, YOSHIMURA M: Endothelin enhances delayed potassium current via phospholipase C in guinea pig ventricular myocytes. *Am J Physiol* **262**: H345-H354, 1992.

HILAL-DANDAN R, MERCK ST, LUJAN JP, BRUNTON LL: Coupling of the type A endothelin receptor to multiple responses in adult rat cardiomyocytes. *Mol Pharmacol* **45**: 1183-1190, 1994.

ISENBERG G, HAN S: Gradation of Ca^{2+}-induced Ca^{2+} release by voltage-clamp pulse duration in potentiated guinea-pig ventricular myocytes. *J Physiol Lond* **480**: 423-438, 1994.

ITO N, KAGAYA Y, WEINBERG EO, BARRY WH, LORELL BH: Endothelin and angiotensin II stimulation of Na^+–H^+ exchange is impaired in cardiac hypertrophy. *J Clin Invest* **99**: 125-135, 1997.

KIOWSKI W, SÜTSCH G, HUNZIKER P, MÜLLER P, KIM J, OECHSLIN E, SCHMITT R, JONES R, BERTEL O: Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. *Lancet* **346**: 732-736, 1995.

LEAF DA, BAHL RA, ADKINS RH: Risk of cardiac dysrhythmias in chronic spinal cord injury patients. *Paraplegia* **31**: 571-575, 1993.

LIU S, SCHREUR KD: G protein-mediated suppression of L-type Ca^{2+} current by interleukin-1 beta in cultured rat ventricular myocytes. *Am J Physiol* **268**: C339-C349, 1995.

LIU XZ, XU XM, HU R, DU C, ZHANG SX, McDONALD JW, DONG HX, WU YJ, FAN GS, JACQUIN MF, HSU CY, CHOI DW: Neuronal and glial apoptosis after traumatic spinal cord injury. *J Neurosci* **17**: 5395-5406, 1997.

MEBAZAA A, MAYOUX E, MAEDA K, MARTIN LD, LAKATTA EG, ROBOTHAM JL, SHAH AM: Paracrine effects of endocardial endothelial cells on myocyte contraction mediated via endothelin. *Am J Physiol* **265**: H1841-H1846, 1993.

MYERS J, LEE M, KIRATLI J: Cardiovascular disease in spinal cord injury: an overview of prevalence, risk, evaluation, and management. *Am J Phys Med Rehabil* **86**: 142-152, 2007.

OGAWA T, SASATOMI K, HIRAGATA S, SEKI S, NISHIZAWA O, CHERMANSKY CJ, PFLUG BR, NELSON JB, CHANCELLOR MB, YOSHIMURA N: Therapeutic effects of endothelin-A receptor antagonist on bladder overactivity in rats with chronic spinal cord injury. *Urology* **71**: 341-345, 2008.

PETERS CM, ROGERS SD, POMONIS JD, EGNACZYK GF, KEYSER CP, SCHMIDT JA, GHILARDI JR, MAGGIO JE, MANTYH PW: Endothelin receptor expression in the normal and injured spinal cord: potential involvement in injury-induced ischemia and gliosis. *Exp Neurol* **180**: 1-13, 2003.

PRAKASH M, RAXWAL V, FROELICHER VF, KALISETTI D, VIEIRA A, O'MARA G, MARCUS R, MYERS J, KIRATLI J, PERKASH I: Electrocardiographic findings in patients with chronic spinal cord injury. *Am J Phys Med Rehabil* **81**: 601-608, 2002.

SAKAI S, MIYAUCHI T, SAKURAI T, KASUYA Y, IHARA M, YAMAGUCHI I, GOTO K, SUGISHITA Y: Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. *Circulation* **93**: 1214-1222, 1996.

SALZMAN SK, ACOSTA R, BECK G, MADDEN J, BOXER B, OHLSTEIN EH: Spinal endothelin content is elevated after moderate local trauma in the rat to levels associated with locomotor dysfunction after intrathecal injection. J *Neurotrauma* **13**: 93-101, 1996.

SPINALE FG, WALKER JD, MUKHERJEE R, IANNINI JP, KEEVER AT, GALLAGHER KP: Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. *Circulation* **95**: 1918-1929, 1997.

STEADMAN BW, MOORE KB, SPITZER KW, BRIDGE JH: A video system for measuring motion in contracting heart cells. *IEEE Trans Biomed Eng* **35**: 264-272, 1988.

SUGDEN PH: An overview of endothelin signaling in the cardiac myocyte. J *Mol Cell Cardiol* **35**: 871-886, 2003.

SUGDEN PH, CLERK A: Endothelin signalling in the cardiac myocyte and its pathophysiological relevance. *Curr Vasc Pharmacol* **3**: 343-351, 2005.

SUZUKI M, OHTE N, WANG ZM, WILLIAMS DL JR, LITTLE WC, CHENG CP: Altered inotropic response of endothelin-1 in cardiomyocytes from rats with isoproterenol-induced cardiomyopathy. *Cardiovasc Res* **39**: 589-599, 1998.

TEASELL RW, ARNOLD JM, KRASSIOUKOV A, DELANEY GA: Cardiovascular consequences of loss of supraspinal control of the sympathetic nervous system after spinal cord injury. *Arch Phys Med Rehabil* **81**: 506-516, 2000.

UESUGI M, KASUYA Y, HAMA H, YAMAMOTO M, HAYASHI K, MASAKI T, GOTO K: Endogenous endothelin-1 initiates astrocytic growth after spinal cord injury. *Brain Res* **728**: 255-259, 1996.

UESUGI M, KASUYA Y, HAYASHI K, GOTO K: SB209670, a potent endothelin receptor antagonist, prevents or delays axonal degeneration after spinal cord injury. *Brain Res* **786**: 235-239, 1998.

VITES AM, WASSERSTROM JA: Ca^{2+} influx via Na-Ca exchange and I$_{Ca}$ can both trigger transient contractions in cat ventricular myocytes. *Ann N Y Acad Sci* **779**: 521-524, 1996.

XU J, HSU CY, JUNKER H, CHAO S, HOGAN EL, CHAO J: Kininogen and kinin in experimental spinal cord injury. *J Neurochem* **57**: 975-980, 1991.

YANAGISAWA M, KURIHARA H, KIMURA S, TOMOBE Y, KOBAYASHI M, MITSUI Y, YAZAKI K, GOTO Y, MASAKI T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature* **332**: 411-415, 1988.